ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors

Oruka Therapeutics, Inc. (ORKA) announced an update on their ongoing clinical study.

The study, titled “Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants,” aims to test how safe ORKA-001 is and how it moves through the body. It is an early step that helps Oruka Therapeutics, Inc. decide if the drug can move into patient trials.

ORKA-001 is a drug given as a shot under the skin in a sterile solution. The study also uses a matching placebo shot so researchers can clearly see which effects come from the drug.

The trial is interventional, meaning researchers actively give a treatment rather than just observing. Participants are randomly assigned to ORKA-001 or placebo in parallel groups, and both they and the investigators are kept blind to who receives what, with the main goal to test safety and drug behavior, not yet effectiveness on disease.

The trial involves single doses of 300 mg, 600 mg, or 1200 mg of ORKA-001 versus placebo. This stepwise dose escalation helps flag any safety issues at lower doses before moving higher.

The study is listed as Phase 1 and designed for healthy volunteers instead of patients. That setup is standard for first-in-human programs and often runs quickly, which can speed up the path to later-stage studies if results are clean.

The record shows the study status as completed, meaning dosing and follow-up are done. The lack of posted results so far suggests data are still being analyzed or kept internal while Oruka plans next steps.

The study was first submitted on November 13, 2024, signaling when Oruka formally entered the clinic with ORKA-001. That date matters for investors tracking how fast the company executes on its pipeline.

The most recent update to the listing was on March 30, 2026, showing the company is maintaining the record and likely refining data or protocol details. The trial’s completion before this update hints that a data readout may be near, even if not yet public.

For Oruka’s stock, a completed first-in-human study without reported issues can lift confidence in management and science, even before detailed numbers come out. If follow-on trials are announced soon, investors may begin to price in a smoother path to Phase 2 and a longer-term revenue story.

In the broader biotech space, many small caps see sharp moves around Phase 1 status changes and updates to ClinicalTrials records. Competitors working on similar modalities could feel pressure if Oruka signals strong safety, as that may attract more capital and strategic interest to ORKA-001.

Overall, this completed Phase 1 trial and the March 2026 update suggest the ORKA-001 program is progressing on schedule, and investors should watch for a formal data release or new trial launch as the next catalysts. The study record remains active and recently updated, with more details available on the ClinicalTrials portal.

To learn more about ORKA’s potential, visit the Oruka Therapeutics, Inc. drug pipeline page.